RCKT revenueQ2 2026$0
RCKT revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Rocket Pharmaceuticals Inc. (RCKT) financials
For the twelve months ended Jun 30, 2026, Rocket Pharmaceuticals Inc. reported $0 of revenue and -$17.25M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$17.25M
- Free cash flow, TTM
- -$170.50M
- EPS, diluted, TTM
- -$0.17
- Cash
- $224.51M
- Market cap
- $268.9M
FY2016FY2025
FY2016FY2025
FY2016FY2025
RCKT revenue and earnings growth
RCKT net incomeQ2 2026$123.21M
RCKT net income was $123.21M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$68.92M a year earlier. For the full fiscal 2025 it was -$223.12M, compared with -$258.75M in fiscal 2024.
RCKT EPSQ2 2026$1.08
RCKT diluted EPS was $1.08 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.62 a year earlier. For the full fiscal 2025 it was -$2.01, compared with -$2.73 in fiscal 2024.
RCKT free cash flowQ2 2026-$39.62M
RCKT free cash flow was -$39.62M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$49.01M a year earlier. For the full fiscal 2025 it was -$190.45M, compared with -$215.59M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $142.01M | $171.24M | $186.34M | $165.57M | $125.48M | $105.44M | $57.91M | $53.27M | $14.92M | $5.99M |
| Selling, general and admin | $86.50M | $101.96M | $73.32M | $58.77M | $41.77M | $28.86M | $18.24M | $17.89M | $4.86M | $1.58M |
| Operating income | -$231.75M | -$273.20M | -$259.66M | -$224.34M | -$167.25M | -$134.30M | -$76.15M | -$71.16M | -$19.77M | -$7.57M |
| Interest expense | $1.89M | $1.89M | $1.88M | $1.86M | $2.98M | $6.97M | $5.96M | $6.04M | $0 | $0 |
| Pre-tax income | -$223.12M | -$258.75M | - | - | - | - | - | - | - | - |
| Income tax | $0 | $0 | $0 | - | - | - | - | - | - | - |
| Net income | -$223.12M | -$258.75M | -$245.59M | -$221.86M | -$169.07M | -$139.70M | -$77.27M | -$74.52M | -$19.58M | -$7.57M |
| EPS, basic | -$2.01 | -$2.73 | -$2.92 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | -$1.89 | -$2.88 | -$1.11 |
| EPS, diluted | -$2.01 | -$2.73 | -$2.92 | -$3.26 | -$2.67 | -$2.52 | -$1.58 | -$1.89 | -$2.88 | -$1.11 |
| Diluted shares | 111.1M | 94.8M | 84.0M | 68.1M | 63.2M | 55.4M | 49.0M | 39.4M | 6.8M | 6.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $77.56M | $165.00M | $57.28M | $141.86M | $234.04M | $298.67M | $186.91M | $112.79M | $18.35M | $9.66M |
| Short-term investments | $111.37M | $208.70M | $317.27M | $215.88M | $156.05M | $185.62M | $118.73M | $94.38M | $0 | $96.67M |
| Current assets | $192.73M | $378.18M | $378.22M | $364.06M | $392.06M | $487.35M | $307.75M | $209.09M | $18.95M | $128.35M |
| Goodwill | $39.15M | $39.15M | $39.15M | $39.20M | $30.82M | $30.82M | $30.82M | $30.82M | $0 | - |
| Total assets | $330.45M | $527.70M | $566.34M | $551.81M | $497.02M | $590.82M | $372.12M | $251.31M | $20.15M | $129.65M |
| Current liabilities | $30.21M | $40.68M | $48.51M | $39.17M | $22.17M | $32.62M | $18.31M | $15.37M | $4.52M | $7.04M |
| Long-term debt | - | - | - | - | $0 | $35.07M | $45.05M | $41.45M | $0 | - |
| Total debt | - | - | - | - | $0 | $35.07M | $45.05M | $41.45M | $0 | - |
| Total liabilities | $53.23M | $64.47M | $73.77M | $62.12M | $42.30M | $87.31M | $64.82M | $57.28M | $4.63M | $56.48M |
| Shareholders' equity | $277.22M | $463.23M | $492.57M | $489.69M | $454.72M | $503.52M | $307.30M | $194.04M | $15.52M | $8.37M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$190.01M | -$209.72M | -$194.92M | -$178.14M | -$121.16M | -$74.64M | -$64.66M | -$53.79M | -$15.96M | -$5.50M |
| Capital expenditures | $440.0K | $5.86M | $16.44M | $8.36M | $7.62M | $20.61M | $23.27M | $1.45M | $760.0K | $335.0K |
| Free cash flow | -$190.45M | -$215.59M | -$211.35M | -$186.50M | -$128.78M | -$95.25M | -$87.93M | -$55.24M | -$16.72M | -$5.84M |
| Investing cash flow | $103.77M | $131.71M | -$98.07M | -$69.33M | $18.85M | -$96.59M | -$39.01M | -$5.27M | -$760.0K | -$335.0K |
| Financing cash flow | $148.0K | $185.74M | $208.40M | $155.29M | $37.68M | $282.99M | $177.79M | $153.50M | $25.41M | $16.0K |
| Share repurchases | - | - | - | - | $0 | $72.0K | $0 | $0 | $0 | $0 |
| Stock-based compensation | $37.06M | $43.92M | $39.41M | $31.01M | $29.24M | $18.57M | $13.37M | $13.60M | $1.32M | $274.0K |
| Depreciation and amortization | $8.90M | $7.20M | $4.90M | $3.90M | $3.20M | $1.15M | $426.0K | $330.0K | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -80.5% | -55.9% | -49.9% | -45.3% | -37.2% | -27.7% | -25.1% | -38.4% | -126.2% | -90.5% |
| Return on assets | -67.5% | -49.0% | -43.4% | -40.2% | -34.0% | -23.6% | -20.8% | -29.7% | -97.2% | -5.8% |
| Current ratio | 6.38 | 9.30 | 7.80 | 9.29 | 17.69 | 14.94 | 16.81 | 13.60 | 4.19 | 18.23 |
| Debt to equity | - | - | - | - | 0.00 | 0.07 | 0.15 | 0.21 | 0.00 | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $29.50M | $31.45M | $29.35M | $34.07M | $42.66M | $35.94M | $37.36M | $42.31M | $46.34M | $45.23M | $41.74M | $46.84M |
| Selling, general and admin | $17.43M | $17.06M | $14.68M | $18.35M | $25.02M | $28.45M | $25.34M | $27.11M | $27.37M | $22.15M | $21.54M | $18.59M |
| Operating income | -$46.92M | -$48.51M | -$43.96M | -$52.25M | -$71.15M | -$64.39M | -$62.69M | -$69.42M | -$73.71M | -$67.38M | -$63.28M | -$65.43M |
| Interest expense | $473.0K | $473.0K | $473.0K | $473.0K | $473.0K | $472.0K | $473.0K | $471.0K | $471.0K | $471.0K | $470.0K | $469.0K |
| Pre-tax income | $131.84M | -$47.59M | - | - | -$68.92M | -$61.33M | - | - | - | - | - | - |
| Income tax | $8.62M | $0 | - | - | $0 | $0 | - | - | - | - | - | - |
| Net income | $123.21M | -$47.59M | -$42.54M | -$50.33M | -$68.92M | -$61.33M | -$60.33M | -$66.72M | -$69.65M | -$62.05M | -$59.66M | -$61.90M |
| EPS, basic | $1.09 | -$0.42 | -$0.38 | -$0.45 | -$0.62 | -$0.56 | -$0.62 | -$0.71 | -$0.74 | -$0.66 | -$0.62 | -$0.75 |
| EPS, diluted | $1.08 | -$0.42 | -$0.38 | -$0.45 | -$0.62 | -$0.56 | -$0.62 | -$0.71 | -$0.74 | -$0.66 | -$0.62 | -$0.75 |
| Diluted shares | 114.5M | 112.1M | - | 111.6M | 111.0M | 110.1M | - | 94.2M | 93.7M | 93.5M | - | 82.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $224.51M | $49.61M | $77.56M | $75.95M | $34.18M | $51.17M | $165.00M | $66.96M | $39.97M | $36.64M | $57.28M | $227.03M |
| Short-term investments | $59.24M | $94.77M | $111.37M | $146.81M | $238.68M | $268.35M | $208.70M | $170.06M | $240.22M | $295.04M | $317.27M | $211.51M |
| Current assets | $289.55M | $149.83M | $192.73M | $227.68M | $277.15M | $324.49M | $378.18M | $241.75M | $292.73M | $345.16M | $378.22M | $446.87M |
| Goodwill | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M | $39.15M |
| Total assets | $423.10M | $285.41M | $330.45M | $368.03M | $420.98M | $471.07M | $527.70M | $393.69M | $446.41M | $499.44M | $566.34M | $598.76M |
| Current liabilities | $31.32M | $24.47M | $30.21M | $31.17M | $43.40M | $35.31M | $40.68M | $39.98M | $37.59M | $32.96M | $48.51M | $33.48M |
| Total liabilities | $54.27M | $47.37M | $53.23M | $54.36M | $66.77M | $58.93M | $64.47M | $63.92M | $61.78M | $57.94M | $73.77M | $57.68M |
| Shareholders' equity | $368.83M | $238.04M | $277.22M | $313.67M | $354.21M | $412.14M | $463.23M | $329.77M | $384.63M | $441.50M | $492.57M | $541.09M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.61M | -$45.39M | -$34.84M | -$50.42M | -$48.96M | -$55.79M | -$46.94M | -$52.10M | -$53.82M | -$56.86M | -$29.34M | -$57.15M |
| Capital expenditures | $8.0K | $93.0K | $80.0K | -$54.0K | $50.0K | $364.0K | $309.0K | $1.59M | $1.93M | $2.04M | $4.65M | $4.66M |
| Free cash flow | -$39.62M | -$45.49M | -$34.92M | -$50.47M | -$49.01M | -$56.15M | -$47.25M | -$53.69M | -$55.75M | -$58.89M | -$33.99M | -$61.80M |
| Investing cash flow | $214.36M | $17.45M | $36.42M | $93.62M | $31.76M | -$58.03M | -$37.87M | $78.92M | $55.62M | $35.03M | -$140.81M | $48.25M |
| Financing cash flow | $150.0K | -$1.0K | $0 | -$67.0K | $215.0K | $0 | $182.85M | $176.0K | $1.53M | $1.18M | $391.0K | $189.49M |
| Stock-based compensation | $7.42M | $8.49M | $6.11M | $9.76M | $10.86M | $10.33M | $11.09M | $11.25M | $11.33M | $10.25M | $9.93M | $10.32M |
| Depreciation and amortization | $1.60M | $1.60M | $1.70M | $2.70M | $2.00M | $2.50M | $1.80M | $1.90M | $1.80M | $1.70M | $1.40M | $1.20M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.24 | 6.12 | 6.38 | 7.30 | 6.39 | 9.19 | 9.30 | 6.05 | 7.79 | 10.47 | 7.80 | 13.35 |
Source: XBRL data Rocket Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-4, first reported Mar 7, 2018.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
RCKT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RCKT | $0 | - | -$17.25M | - | $268.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
RCKT FAQ
7 questionsWhat is RCKT revenue?
Rocket Pharmaceuticals Inc. (RCKT) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $0.Is RCKT profitable?
No. Rocket Pharmaceuticals Inc. reported a net loss of $17.25M for the twelve months ended Jun 30, 2026.How much cash and debt does RCKT have?
Rocket Pharmaceuticals Inc. reported $224.51M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is RCKT free cash flow?
Rocket Pharmaceuticals Inc. generated -$170.50M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$170.27M less capital expenditures.What is RCKT earnings per share?
Diluted earnings per share were -$0.17 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did RCKT last report financial results?
The latest statements here come from Rocket Pharmaceuticals Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this RCKT financial data come from?
Quantisnow builds these statements from the structured XBRL data Rocket Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.